Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Balstilimab + Botensilimab + GS-1423 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Balstilimab | AGEN-2034|AGEN2034 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Balstilimab (AGEN2034) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 ligand (CD274), potentially resulting in enhanced anti-tumor immune response (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3086-3086). | |
Botensilimab | AGEN1181|AGEN 1181|AGEN-1181 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | Botensilimab (AGEN1181) is an antibody that targets CTLA4, potentially resulting in increased anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2021;9). | |
GS-1423 | AGEN1423|AGEN 1423|AGEN-1423|GS1423|GS 1423|Dalutrafusp alfa | CD73 Antibody 12 TGFB (Pan) Antibody 5 | GS-1423 is an aglycosylated bispecific antibody that targets CD73 and TGFbeta, potentially resulting in antitumor activity (PMID: 36746510). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06300463 | Phase II | Balstilimab + Botensilimab + GS-1423 Balstilimab + Botensilimab | Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | Recruiting | USA | 0 |